Douglas A Dedera

US Patent:

7109030, Sep 19, 2006

Filed:

Aug 12, 2002

Appl. No.:

10/218325

Inventors:

Douglas A. Dedera - Castro Valley CA, US
Victoria Yamazaki - Redwood Shores CA, US
Vinod Asundi - Foster City CA, US
Chenghua Liu - San Jose CA, US
Y. Tom Tang - San Jose CA, US
Radoje T. Drmanac - Palo Alto CA, US

Assignee:

Nuvelo, Inc. - San Carlos CA

International Classification:

C12N 15/00
G01N 33/53
A61K 38/00
C07K 14/435

US Classification:

435325, 435 71, 435 72, 4353201, 435 691, 530350, 530399, 514 12

Abstract:

The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to novel human secreted IGFBP-like polypeptides. Other aspects of the invention include vectors containing processes for producing novel human secreted IGFBP-like polypeptides, compositions, and methods of use for such polypeptides including in cancer.

US Patent:

7378253, May 27, 2008

Filed:

Jan 11, 2006

Appl. No.:

11/330768

Inventors:

Douglas Dedera - Castro Valley CA, US
Jian Rui Wang - San Jose CA, US
Peter Emtage - Edmonton, CA

Assignee:

Novelo, Inc. - San Carlos CA

International Classification:

G01N 33/53

US Classification:

435 723, 435 71, 435 721

Abstract:

Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of disorders associated with CD84Hy1 protein-expressing cells are described.

US Patent:

20030215453, Nov 20, 2003

Filed:

May 14, 2002

Appl. No.:

10/146619

Inventors:

Douglas Dedera - Castro Valley CA, US
Huang-Tsu Chen - Cupertino CA, US
Ching-Yi Wan - Alviso CA, US

International Classification:

A61K039/395
A61K039/00
C12Q001/68
G01N033/574
A61K048/00

US Classification:

424/155100, 424/185100, 514/044000, 435/006000, 435/007230

Abstract:

Certain cells, including types of cancer cells such as B-cell lymphoma, T-cell lymphoma, T-cell leukemia, and non-Hodgkin's lymphoma, are capable of expressing VpreB1 RNA. Immunotargeting using VpreB1 polypeptides, nucleic acids encoding for VpreB1 polypeptides and anti-VpreB1 antibodies provides a method of killing or inhibiting that growth of cancer cells that express the VpreB1 protein. Methods of immunotherapy and diagnosis of disorders associated with VpreB1 protein-expressing cells, such as B-cell lymphoma, T-cell lymphoma, T-cell leukemia, and non-Hodgkin's lymphoma, are described.

US Patent:

20040005317, Jan 8, 2004

Filed:

Dec 19, 2002

Appl. No.:

10/327413

Inventors:

Douglas Dedera - Castro Valley CA, US
Peter Emtage - Sunnyvale CA, US

International Classification:

A61K039/395

US Classification:

424/144100

Abstract:

Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of disorders associated with CD84Hy1protein-expressing cells are described.

US Patent:

20040023870, Feb 5, 2004

Filed:

Dec 19, 2002

Appl. No.:

10/327491

Inventors:

Douglas Dedera - Castro Valley CA, US
Peter Emtage - Sunnyvale CA, US

International Classification:

A61K039/395
A61K038/17

US Classification:

514/012000, 424/144100

Abstract:

Certain cells, including types of cancer cells such as B-cell lymphomas, T cell lymphomas, Hodgkin's disease and myeloid leukemias, are capable of expressing Toll-like Receptor 9 (TLR9) or Toll-like Receptor 10 (TLR10) mRNA. Immunotargeting using TLR9 or TLR10 polypeptides, nucleic acids encoding for TLR9 or TLR10 polypeptides and anti-TLR9 or anti-TLR10 antibodies provides a method of killing or inhibiting that growth of cancer cells that express the TLR9 or TLR1O protein. Methods of immunotherapy and diagnosis of disorders associated with TLR9 or TLR1O protein-expressing cells, such as B-cell lymphoma, T cell lymphoma, acute myeloid leukemia, Hodgkin's disease, B cell leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia and myelodysplastic syndromes, are described.

US Patent:

20050281813, Dec 22, 2005

Filed:

Jul 19, 2005

Appl. No.:

11/185567

Inventors:

Douglas Dedera - Castro Valley CA, US
Peter Emtage - Edmonton, CA

Assignee:

NUVELO, Inc. - Sunnyvale CA

International Classification:

A61K038/17
A61K039/395

US Classification:

424143100, 514002000

Abstract:

Certain cells, including types of cancer cells such as B-cell lymphomas, T cell lymphomas, Hodgkin's disease and myeloid leukemias, are capable of expressing Toll-like Receptor 9 (TLR9) or Toll-like Receptor 10 (TLR10) mRNA. Immunotargeting using TLR9 or TLR10 polypeptides, nucleic acids encoding for TLR9 or TLR10 polypeptides and anti-TLR9 or anti-TLR10 antibodies provides a method of killing or inhibiting that growth of cancer cells that express the TLR9 or TLR10 protein. Methods of immunotherapy and diagnosis of disorders associated with TLR9 or TLR10 protein-expressing cells, such as B-cell lymphoma, T cell lymphoma, acute myeloid leukemia, Hodgkin's disease, B cell leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia and myelodysplastic syndromes, are described.

US Patent:

20090053136, Feb 26, 2009

Filed:

Apr 8, 2008

Appl. No.:

12/099621

Inventors:

Douglas Dedera - Castro Valley CA, US
Peter C.R. Emtage - San Diego CA, US

Assignee:

NUVELO, INC. - San Carlos CA

International Classification:

A61K 51/00
A61K 39/395
A61K 39/00
A61K 35/12
A61K 31/7088
C12Q 1/02
C12Q 1/68
C07K 16/18
A61P 31/00

US Classification:

424 149, 4241741, 4241561, 4241331, 4241781, 4242771, 424 937, 514 44, 424 9321, 435 29, 435 6, 5303871, 53038885, 5303873, 5303913, 5303917

Abstract:

Certain cells, including types of cancer cells such as lymphomas, are capable of expressing high levels of CD84Hy1. Immunotargeting using CD84Hy1 polypeptides, nucleic acids encoding for CD84Hy1 polypeptides and anti-CD84Hy1 antibodies provides a method of killing or inhibiting that growth of CD84HY1 Protein-expressing cancer cells. Methods of immunotherapy and diagnosis of disorders associated with CD84Hy1 protein-expressing cells are described.